What should you know about smoldering multiple myeloma?

This finding is different from active multiple myeloma, which causes organ or tissue problems. It is also different from a harmless antibody change because the marrow findings are more pronounced. The distinction depends on blood and urine testing, bone marrow examination, and imaging interpreted together.

Some people remain stable for a long time; others develop active disease. Monitoring helps the care team notice changing blood markers, anemia, kidney problems, high calcium, or bone changes before deciding whether treatment is needed.

Keep the follow-up plan arranged with a hematology team. Bring a list of medicines and tell the team about new bone pain, unusual tiredness, repeated infections, thirst, constipation, changes in urination, or unexplained weight change. Follow-up may include blood counts, kidney and calcium checks, protein measurements, urine testing, and repeat imaging when clinically appropriate.

Treatment is not automatically started when smoldering disease is found. If active myeloma develops, options can include targeted therapy, chemotherapy, radiotherapy, bone-strengthening therapy, cellular treatment, or transplant approaches, selected for the individual situation.

Contact the oncology team promptly for new or worsening back or rib pain, weakness, numbness, difficulty walking, marked thirst, confusion, reduced urine, fever, or breathlessness. Sudden severe back pain with leg weakness or loss of bladder or bowel control needs emergency assessment because nerve or spinal pressure must be addressed quickly.

Ask which test results support smoldering disease, what changes would indicate active myeloma, how often follow-up is needed, and which symptoms should trigger a same-day call. You can also ask whether imaging, a bone marrow review, or a specialist opinion would clarify your risk and monitoring plan.